Ibnsina Pharma Past Earnings Performance
Past criteria checks 4/6
Ibnsina Pharma's earnings have been declining at an average annual rate of -3.4%, while the Healthcare industry saw earnings growing at 4.1% annually. Revenues have been growing at an average rate of 20.5% per year. Ibnsina Pharma's return on equity is 24.5%, and it has net margins of 0.7%.
Key information
-3.4%
Earnings growth rate
-0.09%
EPS growth rate
Healthcare Industry Growth | 0.4% |
Revenue growth rate | 20.5% |
Return on equity | 24.5% |
Net Margin | 0.7% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ibnsina Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 48,546 | 361 | 1,834 | 0 |
30 Jun 24 | 42,066 | 246 | 1,640 | 0 |
31 Mar 24 | 37,680 | 195 | 1,491 | 0 |
31 Dec 23 | 33,949 | 173 | 1,373 | 0 |
30 Sep 23 | 30,258 | 184 | 1,301 | 0 |
30 Jun 23 | 26,700 | 174 | 1,226 | 0 |
31 Mar 23 | 23,775 | 144 | 1,189 | 0 |
31 Dec 22 | 22,264 | 136 | 1,142 | 0 |
30 Sep 22 | 21,792 | 180 | 987 | 0 |
30 Jun 22 | 21,870 | 269 | 923 | 0 |
31 Mar 22 | 22,309 | 293 | 901 | 0 |
31 Dec 21 | 21,733 | 286 | 784 | 0 |
30 Sep 21 | 20,729 | 218 | 869 | 0 |
30 Jun 21 | 19,929 | 197 | 862 | 0 |
31 Mar 21 | 18,992 | 184 | 808 | 0 |
31 Dec 20 | 18,679 | 184 | 847 | 0 |
30 Sep 20 | 18,373 | 233 | 793 | 0 |
30 Jun 20 | 17,928 | 258 | 774 | 0 |
31 Mar 20 | 17,317 | 276 | 720 | 0 |
31 Dec 19 | 16,600 | 269 | 689 | 0 |
30 Sep 19 | 15,820 | 287 | 687 | 0 |
30 Jun 19 | 14,919 | 264 | 643 | 0 |
31 Mar 19 | 14,169 | 254 | 599 | 0 |
31 Dec 18 | 13,324 | 242 | 569 | 0 |
30 Sep 18 | 12,305 | 181 | 517 | 0 |
30 Jun 18 | 11,462 | 177 | 484 | 0 |
31 Mar 18 | 10,561 | 174 | 462 | 0 |
31 Dec 17 | 9,586 | 162 | 432 | 0 |
30 Sep 17 | 8,917 | 157 | 415 | 0 |
31 Dec 16 | 7,206 | 102 | 346 | 0 |
31 Dec 15 | 5,326 | 57 | 250 | 0 |
31 Dec 14 | 4,197 | 38 | 194 | 0 |
31 Dec 13 | 3,274 | 35 | 145 | 0 |
Quality Earnings: ISPH has high quality earnings.
Growing Profit Margin: ISPH's current net profit margins (0.7%) are higher than last year (0.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ISPH's earnings have declined by 3.4% per year over the past 5 years.
Accelerating Growth: ISPH's earnings growth over the past year (96%) exceeds its 5-year average (-3.4% per year).
Earnings vs Industry: ISPH earnings growth over the past year (96%) exceeded the Healthcare industry 50.8%.
Return on Equity
High ROE: Whilst ISPH's Return on Equity (24.48%) is high, this metric is skewed due to their high level of debt.